Cargando…

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade

Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kroemer, Guido, Kepp, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565809/ https://www.ncbi.nlm.nih.gov/pubmed/34745770 http://dx.doi.org/10.1080/2162402X.2021.1996686

Ejemplares similares

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
por: Kepp, Oliver, et al.
Publicado: (2020)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

A novel platinum-based chemotherapeutic inducing immunogenic cell death
por: Kepp, Oliver, et al.
Publicado: (2020)

Immunogenic cell death inducers as anticancer agents
por: Kepp, Oliver, et al.
Publicado: (2014)

Ferroptosis becomes immunogenic: implications for anticancer treatments
por: Tang, Daolin, et al.
Publicado: (2020)

Arsenic trioxide as an inducer of immunogenic cell death
por: Kepp, Oliver, et al.
Publicado: (2023)

An unexpected link between immunogenic cell death and inhibition of gene transcription
por: Humeau, Juliette, et al.
Publicado: (2020)

Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death
por: Gomes-da-Silva, Lígia C., et al.
Publicado: (2020)

Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients
por: Kroemer, Guido, et al.
Publicado: (2021)

Immunogenic cell death in radiation therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2013)

Redaporfin induces immunogenic cell death by selective destruction of the endoplasmic reticulum and the Golgi apparatus
por: Gomes-da-Silva, Lígia Catarina, et al.
Publicado: (2018)

Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
por: Wang, Yan, et al.
Publicado: (2020)

Prevention and treatment of cancers by tumor antigen-expressing Staphylococcus epidermidis
por: Kepp, Oliver, et al.
Publicado: (2023)

Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy
por: Ma, Yuting, et al.
Publicado: (2013)

Novel galenic formulations for delivering immunochemotherapies: kill intelligently, remove the checkpoint and let the T cells in!
por: Kepp, Oliver, et al.
Publicado: (2020)

Immunogenic cell death in cancer: concept and therapeutic implications
por: Galluzzi, Lorenzo, et al.
Publicado: (2023)

TP53 and MTOR crosstalk to regulate cellular senescence
por: Galluzzi, Lorenzo, et al.
Publicado: (2010)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy
por: Bourgin, Melanie, et al.
Publicado: (2022)

Secreted calreticulin mutants subvert anticancer immunosurveillance
por: Liu, Peng, et al.
Publicado: (2019)

Tumor-infiltrating lymphocytes for melanoma immunotherapy
por: Kepp, Oliver, et al.
Publicado: (2023)

Isobacachalcone induces autophagy and improves the outcome of immunogenic chemotherapy
por: Wu, Qi, et al.
Publicado: (2020)

Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade
por: Liu, Jiao, et al.
Publicado: (2022)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Detection of immunogenic cell death and its relevance for cancer therapy
por: Fucikova, Jitka, et al.
Publicado: (2020)

Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress
por: Michaud, Mickaël, et al.
Publicado: (2014)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

Immunological effects of chemotherapy in spontaneous breast cancers
por: Kroemer, Guido, et al.
Publicado: (2013)

Conventional type 1 dendritic cells (cDC1) in cancer immunity
por: Liu, Peng, et al.
Publicado: (2023)

(18)F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer
por: Borm, Frank Johannes, et al.
Publicado: (2020)

Necrocide 1 mediates necrotic cell death and immunogenic response in human cancer cells
por: Zhang, Jing, et al.
Publicado: (2023)

Is PD-1 blockade a potential therapy for HBV?
por: Féray, Cyrille, et al.
Publicado: (2019)

Impact of local anesthetics on epigenetics in cancer
por: Bezu, Lucillia, et al.
Publicado: (2022)

Histamine antagonists promote cancer immunosurveillance
por: Liu, Peng, et al.
Publicado: (2023)

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
por: Gujar, Shashi, et al.
Publicado: (2018)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
por: Roper, Nitin, et al.
Publicado: (2021)

Combinatorial Strategies for the Induction of Immunogenic Cell Death
por: Bezu, Lucillia, et al.
Publicado: (2015)

Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
por: Ferrere, Gladys, et al.
Publicado: (2021)

AKT as a therapeutic target for autophagy induction and cancer therapy
por: Wu, Qi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b9s4mjrdtuneb0tfb1gtaf2m5m